Message :
Required fields
CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021.
Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020):
Consolidated net revenues of $85.3 million, up 49% year-over-year
Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year
Diagnostics segment net revenues decreased 9% year-over-year to $31.9 million, up 5% from the first quarter of fiscal 2021
Signed agreement for 2nd grant from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx
SM) initiative - $5.5 million for ramping manufacturing of Revogene
® SARS-CoV-2 Assay
® Campy assay
Launched first Air-Dryable sample specific Master Mix for Blood